CTOs on the Move

Rigel Pharmaceuticals

www.rigel.com

 
Rigel Pharmaceuticals, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.rigel.com
  • 1180 Veterans Blvd
    South San Francisco, CA USA 94080
  • Phone: 650.624.1100

Executives

Name Title Contact Details

Similar Companies

Carol Cole Company

Carol Cole Company is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Translate Bio

Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Our proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. We believe that our MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. Our two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.

Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is a clinical stage private biopharma with prodrug platforms that address opioid use disorder. Trypsin-Activated Abuse Protection (TAAP) technology forms an opioid prodrug that can only be activated through a 2-step internal digestive process, and therefore cannot be abused by chewing, snorting or IV administration.

Alto Neuroscience

Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster. Our artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.